1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS

Objective: To compare brain metabolite levels in patients with primary progressive (PP) and relapsing remitting (RR) MS and controls. Hypotheses: (1) creatine (Cr), a putative marker of gliosis, is elevated and N-acetylaspartate (NAA), a putative marker of axonal density and functional integrity, is reduced in PPMS lesions and normal appearing white matter (NAWM) compared to control white matter; (2) The pattern of metabolite change in PPMS is different than in RRMS. Methods: MRI and proton magnetic resonance spectroscopic imaging (1H MRSI) were collected from 15 PPMS patients, 13 RRMS patients, and 20 controls. Results: Cr was increased in PPMS NAWM compared to controls (P=0.035), and compared to RRMS NAWM (P=0.038). Cr was increased in focal MRI lesions from PPMS compared to lesions from RRMS (P=0.044) and compared to control white matter (P=0.041). NAA was similarly reduced in PPMS and RRMS NAWM compared to control. NAA was similarly reduced in PPMS and RRMS lesions, compared to control white matter. Conclusions: Creatine is higher in PPMS than RRS NAWM and focal lesions. This observation is consistent with the notion that progressive disability in PPMS reflects increased gliosis and axonal loss whereas disability in RRMS reflects the cumulative effects of acute inflammatory lesions and axonal loss.

[1]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  Jullie W Pan,et al.  Quantitative spectroscopic imaging of the human brain , 1998, Magnetic resonance in medicine.

[3]  G. Barker,et al.  The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis , 1997, Journal of Neurology.

[4]  A J Thompson,et al.  PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS , 1997 .

[5]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[6]  R. Tarducci,et al.  Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. , 1999, Brain : a journal of neurology.

[7]  C. Raine.  The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesion , 1994, Annals of neurology.

[8]  G. McDonnell,et al.  Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK , 1998, Journal of neurology, neurosurgery, and psychiatry.

[9]  I. Allen,et al.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.

[10]  G B Matson,et al.  Reduced phase encoding in spectroscopic imaging , 1994, Magnetic resonance in medicine.

[11]  A. Thompson,et al.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis , 1991, Annals of neurology.

[12]  V. Govindaraju,et al.  Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imaging , 1998, Magnetic resonance in medicine.

[13]  E. Waubant,et al.  Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. , 1999, Archives of neurology.

[14]  M W Weiner,et al.  Spectroscopic imaging display and analysis. , 1992, Magnetic resonance imaging.

[15]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[16]  Jullie W Pan,et al.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.

[17]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.

[18]  J. Hillert,et al.  An immunogenetic heterogeneity in multiple sclerosis , 1991, Journal of Neuroimmunology.

[19]  G. Barker,et al.  Spinal cord atrophy and disability in MS , 1998, Neurology.

[20]  G J Barker,et al.  Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. , 1997, Brain : a journal of neurology.

[21]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[22]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[23]  G. Barker,et al.  1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[24]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[25]  A J Thompson,et al.  A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.

[26]  M. Filippi,et al.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. , 1995 .

[27]  M W Weiner,et al.  1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.

[28]  N. Jagannathan,et al.  Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. , 1996, Magnetic resonance imaging.

[29]  M Noble,et al.  Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.

[30]  G. McDonnell,et al.  Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis , 1998, Journal of Neuroimmunology.

[31]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[32]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[33]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[34]  B. Weinshenker,et al.  The natural history of multiple sclerosis. , 1995, Neurologic clinics.

[35]  T. Olsson,et al.  Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Poland,et al.  Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. , 1998, Archives of neurology.

[37]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[38]  A. Thompson,et al.  Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.